CA-NETAPP
26.6.2024 14:01:30 CEST | Business Wire | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that NetApp ONTAP® Autonomous Ransomware Protection with Artificial Intelligence (ARP/AI) has received a AAA rating from SE Labs, an independently-owned and run testing company that assesses security products and services. SE Labs validated the protection effectiveness of NetApp ARP/AI with 99 percent recall—a metric that measures malware detection rates—for ransomware attacks, while noting the absence of false positives.
When responding to ransomware attacks, seconds can make the difference between ensuring continuity and a massive business disruption. Organizations need fast, automated, and accurate detection and response capabilities built into their primary storage systems to minimize the damage done by lost production data and downtime. NetApp ARP/AI, with its AI-powered ransomware detection capability, addresses this gap by providing real-time detection and response to minimize the impact of cybersecurity threats.
SE Labs rigorously tested NetApp ARP/AI against hundreds of known ransomware variants with impressive results. NetApp ARP/AI demonstrated 99 percent detection of advanced ransomware attacks. NetApp ARP/AI also achieved 100 percent detection of legitimate files without flagging any false positives, indicating a strong ability to operate in a business context without contributing to alert fatigue.
Ensuring data is secure against internal and external threats is a critical part of making data infrastructure intelligent which then empowers customers to turn disruption into opportunity. This validation of NetApp’s AI-powered ransomware detection capabilities underscores how NetApp is staying at the forefront of AI innovation by both enabling AI adoption and applying AI to data services. NetApp’s newly released more powerful, all-flash storage systems help enterprises leverage their data to drive AI workloads, built on NetApp’s secure storage infrastructure.
"NetApp has passed a significant milestone in the fight against ransomware as the first and only storage vendor to offer AI-driven on-box ransomware detection with externally validated top-notch protection effectiveness,” said Dr. Arun Gururajan, Vice President, Research & Data Science at NetApp. “Ransomware detection methodologies that rely only on backup data are too slow to effectively mitigate the risks businesses face from cybersecurity threats. NetApp ARP/AI hardens enterprise storage by providing robust, built-in detection capabilities that can respond to ransomware threats in real time. The AAA rating we achieved from SE Labs is the result of our commitment to innovation in intelligent data infrastructure and our drive to find new ways to make NetApp the most secure storage on the planet.”
By embedding ransomware detection in storage, NetApp ARP/AI helps customers improve their cyber resilience while reducing the operational burden and skills required to maintain their intelligent data infrastructure. NetApp ARP/AI’s detection technology continuously adapts and evolves as new ransomware variants are discovered. This continuous retraining on the latest ransomware strains ensures that NetApp ARP/AI remains at the forefront of protection effectiveness, offering organizations a future-proof defense against the dynamic ransomware landscape.
To see the full results of the tests, read the SE Labs Report.
NetApp ARP/AI is currently in tech preview. Customers can request to participate in the tech preview by reaching out to their NetApp sales representative.
Additional Resources
- NetApp, the First and Leading AI-Powered Autonomous Ransomware Protection Native to Storage Achieves Remarkable AAA Rating and 99% Detection Accuracy and 100% Legitimate Accuracy in SE Labs Validation Testing
- Protect, Detect, Recover; Guaranteed
About NetApp
NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240626446291/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
